Clinical trial
Botswana TDF/FTC Oral HIV Prophylaxis Trial
NCT00448669 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00448669 |
|---|---|
| Title | Botswana TDF/FTC Oral HIV Prophylaxis Trial |
| Official title | Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana |
| Acronym | TDF2 |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Botswana Ministry of Health Gilead Sciences Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet |
| Enrollment | 1,219 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Mar 19, 2007 |
| Last update posted | Feb 5, 2020 |
| Countries | Botswana, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: